An observational study in Treatment Resistant Depression (TRD), sponsored by University of Utah. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by University of Utah · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 205 studies in Depressive Disorder, Treatment-Resistant with a site in United States — 43 open to participants now, 65 under way, 6 of them phase 3. Depressive Disorder, Treatment-Resistant · United States.
Among the 205 studies in Depressive Disorder, Treatment-Resistant with a site in United States, this one is the 14th largest by enrollment of the 23 observational ones that give a count, is one of 12 that started in 2025, is one of 23 observational ones, and was the 182nd registered.
449 studies on the registry are indexed under Depressive Disorder, Treatment-Resistant; 147 are open to participants now.
Browse Depressive Disorder, Treatment-Resistant studies →43 of the 205 studies in Depressive Disorder, Treatment-Resistant with a site in United States are open now. Recruiting first, the newest first:
NeuroRx, Inc. · Sites in United States
Ages 18–80
Mayo Clinic · Sites in United States
Ages 22–60
Motif Neurotech, Inc. · Sites in United States
Ages 22–85
BrainHealth Solutions, Inc. · Sites in United States
Ages 65+
Mclean Hospital · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 115 Depressive Disorder, Treatment-Resistant studies recruiting now, 27 (23%) set no upper age limit and 76 (66%) stop at 75 or younger; 1 takes children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
205 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 58 · Phase 3 23 · Phase 4 17
First in 2001; this study’s year is marked. 12 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 50 is below the median of 73 across 50 observational studies indexed under Depressive Disorder, Treatment-Resistant.
Median enrollment 38 across the 181 interventional studies, 66 across the 23 observational. Of the 120 that completed or were terminated, 70 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
57 of 205 have an industry lead sponsor. The 10 most frequent:
University of Utah is the lead sponsor of 997 studies on the registry; 176 are open to participants now.
Of its 114 completed or terminated interventional studies of FDA-regulated products, 69 (61%) have results posted.
University of Utah has 4 studies filed under Depressive Disorder, Treatment-Resistant — fewer than ten, so there is no comparison to draw.
20 of the studies in Depressive Disorder, Treatment-Resistant with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04041479Phase 3Weill Medical College of Cornell UniversityBiomarker-guided rTMS for Treatment Resistant Depression | 2027-04 |
| NCT04684706University of PennsylvaniaCompressed Intermittent Theta Burst Stimulation | 2026-11-30 |
| NCT06938841University of California, San DiegoMaintenance rTMS for Depression (Maitr-De) | 2026-11-30 |
| NCT03573349Mayo ClinicKetamine Associated ACC GABA and Glutamate Change and Depression Remission: | 2026-12 |
| NCT07310381Stanford UniversityVagus Nerve Stimulation (VNS) Electroencephalogram (EEG) Protocol Supplement | 2026-12-31 |
Add all 20 to your calendar (.ics) → With an account.
Among the 205 studies in Depressive Disorder, Treatment-Resistant with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will be conducted at HMHI's treatment resisted mood disorder clinic (TRMD) and will collect data from patient's receiving ketamine infusion treatments (KIT) for TRD. Data will be collected for two separate cohorts, representing two different stages in treatment, acute series (initial 6-12 session) and maintenance (will collect data from up to 6 maintenance sessions).
The goal of the study will be to explore to role of music in this treatment modality and how personal choice and properties of music played during the treatments affects experiential and clinical outcomes.
Patient age 18 or older who are getting KIT, or who plan to start KIT at the HMHI TRMD clinic.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients that listen to the music being played in the clinic on speakers
Patient that listen to their personally chosen playlist
Patient who do not want to listen to music during their treatment
Quick Inventory of Depressive Symptoms
QIDS; this 16-item scale has scores ranging from 0 to 27. Higher scores imply worse depression. It is interpreted as follows: * 0 - 5: Normal / No Depression (or minimal symptoms) * 6 - 10: Mild Depression * 11 - 15: Moderate Depression * 16 - 20: Severe Depression * 21 - 27: Very Severe Depression
Time frame: Baseline and prior to each infusion (up to two infusions per week), for up to 12 infusion sessions during the acute treatment phase, and for up to six weekly maintenance infusions
CEQ-7
Challenging Experience Questionnaire 7-Item. Scores range from 0 to 35. Higher scores indicate a more challenging experience (typically associated with psychedelic or dissociative compound administration)
Time frame: within 24 hours of each infusion for up to 12 twice-weekly infusions during the acute phase and up to 6 weekly maintenance infusions
MEQ-4
4-item Mystical Experience Questionnaire. Scores range from 0 to 20. Higher scores indicate a more mystical or more intensely spiritual experience.
Time frame: up to 12 months
Ran from Jul 2025 to primary completion in Jul 2026, 11 months.
Of 33 observational studies under Depressive Disorder, Treatment-Resistant, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 65. This study's 11 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Depressive Disorder, Treatment-Resistant →